5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC

J. G. Eriksen, C. Maare, J. Johansen, H Primdahl, J. Evensen, C A Kristensen, Lisbeth Juhler Andersen, J Overgaard

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
ArtikelnummerOC-0271
TidsskriftRadiotherapy & Oncology
Vol/bind127
Udgave nummerSupplement 1
Sider (fra-til)S137-S138
Antal sider2
ISSN0167-8140
DOI
StatusUdgivet - 2018
Begivenhed37th Meeting of the European-Society-for-Radiotherapy-and-Oncology - Barcelona, Spanien
Varighed: 20 apr. 201824 apr. 2018

Konference

Konference37th Meeting of the European-Society-for-Radiotherapy-and-Oncology
LandSpanien
ByBarcelona
Periode20/04/201824/04/2018

Citer dette

Eriksen, J. G., Maare, C., Johansen, J., Primdahl, H., Evensen, J., Kristensen, C. A., ... Overgaard, J. (2018). 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. Radiotherapy & Oncology, 127(Supplement 1), S137-S138. [OC-0271]. https://doi.org/10.1016/S0167-8140(18)30581-4
Eriksen, J. G. ; Maare, C. ; Johansen, J. ; Primdahl, H ; Evensen, J. ; Kristensen, C A ; Andersen, Lisbeth Juhler ; Overgaard, J. / 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. I: Radiotherapy & Oncology. 2018 ; Bind 127, Nr. Supplement 1. s. S137-S138.
@article{30f2bd5df8e741de9fcb49dc95be89c6,
title = "5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC",
author = "Eriksen, {J. G.} and C. Maare and J. Johansen and H Primdahl and J. Evensen and Kristensen, {C A} and Andersen, {Lisbeth Juhler} and J Overgaard",
year = "2018",
doi = "10.1016/S0167-8140(18)30581-4",
language = "English",
volume = "127",
pages = "S137--S138",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier",
number = "Supplement 1",

}

Eriksen, JG, Maare, C, Johansen, J, Primdahl, H, Evensen, J, Kristensen, CA, Andersen, LJ & Overgaard, J 2018, '5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC' Radiotherapy & Oncology, bind 127, nr. Supplement 1, OC-0271, s. S137-S138. https://doi.org/10.1016/S0167-8140(18)30581-4

5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. / Eriksen, J. G.; Maare, C.; Johansen, J.; Primdahl, H; Evensen, J. ; Kristensen, C A; Andersen, Lisbeth Juhler; Overgaard, J.

I: Radiotherapy & Oncology, Bind 127, Nr. Supplement 1, OC-0271, 2018, s. S137-S138.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC

AU - Eriksen, J. G.

AU - Maare, C.

AU - Johansen, J.

AU - Primdahl, H

AU - Evensen, J.

AU - Kristensen, C A

AU - Andersen, Lisbeth Juhler

AU - Overgaard, J

PY - 2018

Y1 - 2018

U2 - 10.1016/S0167-8140(18)30581-4

DO - 10.1016/S0167-8140(18)30581-4

M3 - Conference abstract in journal

VL - 127

SP - S137-S138

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

IS - Supplement 1

M1 - OC-0271

ER -

Eriksen JG, Maare C, Johansen J, Primdahl H, Evensen J, Kristensen CA et al. 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. Radiotherapy & Oncology. 2018;127(Supplement 1):S137-S138. OC-0271. https://doi.org/10.1016/S0167-8140(18)30581-4